Mucosal vaccine composition
US10391167B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 2, 2014 |
| Grant date | Aug 27, 2019 |
| Priority date | — |
| Expiry date | Oct 2, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/32634
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to a method for inducing humoral immunity in a human or animal, that includes administering to the human or animal a mucosal vaccine composition to a mucous membrane selected from the group consisting of a human or animal intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, and rectal mucous membrane. The mucosal vaccine composition includes at least one antigen derived from a pathogen; and as an adjuvant, a lipopolysaccharide derived from at least one gram-negative bacterium selected from the group consisting of Pantoea, Acetobacter, Zymomonas, and Xanthomonas, or a salt of the lipopolysaccharide, wherein the mass ratio between a total mass of the adjuvant and a total mass of the antigen is 0.002 to 500. The mucosal vaccine composition is administered in an amount effective to induce humoral immunity in the human or animal.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.